| Literature DB >> 27335363 |
Onyee Chan1, Hao Chen2, Ravitharan Krishnadasan3, Faiz Anwer3.
Abstract
Initial treatment of chronic phase chronic myeloid leukaemia is straightforward in today's era of tyrosine kinase inhibitors. However, managing refractory cases remain a major challenge due to the multiple factors that can influence decision-making, including medication tolerance, disease burden, mutation status, comorbidities, availability of donor, and fitness for an ablative conditioning. We report a male patient presenting with chronic phase chronic myeloid leukaemia who was treated with 5 different tyrosine kinase inhibitors either due to intolerance and/or failed response. He subsequently received 2 haploidentical haematopoietic stem cells transplants before achieving complete remission. This case highlights various treatment options, need for vigilant disease monitoring, and the possibility of complete positive response even after many lines of therapy failure. 2016 BMJ Publishing Group Ltd.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27335363 PMCID: PMC4932415 DOI: 10.1136/bcr-2016-215370
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X